Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

roflumilast

- PMLiVE

Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms

Some patients found the treatment reduced itch and sleep disturbance within just two days

- PMLiVE

Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study

The inflammatory skin condition affects over 26 million people in the US

- PMLiVE

Eli Lilly/Almirall’s Ebglyss shows promise in atopic dermatitis patients with darker skin tones

The inflammatory skin condition occurs in approximately 7.3% of adults in the US

- PMLiVE

FDA unveils new voucher programme to accelerate drug review process

The programme is designed to reduce the review time for companies supporting US national interests

- PMLiVE

Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

These are the first clinical study results for the drug in a large population of patients with darker skin tones

- PMLiVE

Galderma shares positive two-year results for Nemluvio in atopic dermatitis

The chronic inflammatory skin disease affects more than 230 million people worldwide

- PMLiVE

Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis

The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide

- PMLiVE

Organon shares positive long-term results for Vtama cream in atopic dermatitis

The common inflammatory skin disease affects more than 26 million people in the US alone

- PMLiVE

MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

The drug has been authorised to treat patients with moderate-to-severe cases of the skin diseases

EU flag

EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha

- PMLiVE

FDA approves Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

The mosquito-borne viral disease has been reported across many popular travel destinations

- PMLiVE

Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links